These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 4216916)
21. [Causes of failure in neutralization, recovery and social rehabilitation of chronic eliminators of Koch bacilli treated with rifampin and ethambutol]. Barbu Z; Alexa M; Josefovics F Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1978; 27(3):153-9. PubMed ID: 212812 [No Abstract] [Full Text] [Related]
22. [Clinical and bacteriological experimentation with a new antitubercular chemotherapeutic agent: ethambutol]. Serra C; Andreis G G Ital Chemioter; 1966; 13(1):109-27. PubMed ID: 4967318 [No Abstract] [Full Text] [Related]
24. [Liver function in patients with chronic destructive pulmonary tuberculosis during complex treatment with rifampicin and ethambutol]. Kharakter ZhZ; Chertkova MA; Pavlenko AV Probl Tuberk; 1975; (10):44-8. PubMed ID: 1208440 [No Abstract] [Full Text] [Related]
25. [Test of short-term monotherapy in the clinical evaluation of the action of antitubercular agents]. Anastasatu C; Bercea O; Marcian S; Ceicu A Arch Monaldi; 1971; 26(4):291-9. PubMed ID: 5004576 [No Abstract] [Full Text] [Related]
26. [Bacteriological relapse among the previously treated advanced pulmonary tuberculosis patients whose sputum converted to negative by the rifampicin treatment, with special reference to the duration of rifampicin administration (author's transl)]. Yamamoto M; Morishita M; Hirano Y; Nagata A; Yazaki M Kekkaku; 1974 Jul; 49(7):195-9. PubMed ID: 4214961 [No Abstract] [Full Text] [Related]
27. [Ethambutol in the chemotherapy of patients with fibrocavernous tuberculosis of the lungs]. Utkin VV; Poleshchuk AK; Zankisova IG; Mkrtchian SV; Krylova NP; Gridneva SM Probl Tuberk; 1971; 49(7):27-32. PubMed ID: 5005808 [No Abstract] [Full Text] [Related]
28. [Results of 6-month and 9-month treatments with rifampin, isoniazid and ethambutol in cases of newly detected tuberculosis]. Szymanski A; Gaik A Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(3):181-3. PubMed ID: 6273991 [No Abstract] [Full Text] [Related]
29. [Sputum positive conversion among retreatment cases with pulmonary tuberculosis converted to negative by the use of rifampicin (author's transl)]. Ito F; Okochi T; Yamazaki M; Yamamoto Y; Kondo K; Konishiike J; Asahi T Kekkaku; 1979 Jan; 54(1):37-42. PubMed ID: 107360 [No Abstract] [Full Text] [Related]
30. [Bacteriologic results and relapses of sputum-positive reactions in 110 tuberculous patients treated with ethambutol]. Szarewicz-Adamczyk W; Przemyska B; Mysakowska H; Grodzki S; Marciniak T Gruzlica; 1974 Mar; 42(3):221-7. PubMed ID: 4822090 [No Abstract] [Full Text] [Related]
31. [Dynamics of the release of bacilli and the closing of caverns in newly identified tuberculosis patients undergoing different chemotherapeutic regimens]. Muratov VV; Pashkov IuN; Pospelov VV Probl Tuberk; 1981 Dec; (12):30-4. PubMed ID: 6801646 [No Abstract] [Full Text] [Related]
32. Prevalence of initial drug resistance to M. tuberculosis in new sputum positive RNTCP patients. Dhingra VK; Rajpal S; Bhalla P; Yadav A; Jain SK; Hanif M J Commun Dis; 2003 Jun; 35(2):82-9. PubMed ID: 15562953 [TBL] [Abstract][Full Text] [Related]
33. [Results of follow-up on advanced cases of pulmonary tuberculosis converted to negative with rifampicin treatment]. Yamamoto M; Isoe K; Nakamura H; Hirose H; Izumi S Kekkaku; 1972 Nov; 47(11):393-7. PubMed ID: 4630902 [No Abstract] [Full Text] [Related]
34. [Ethambutol in chemotherapy of patients with fibro-cavitary tuberculosis of the lungs]. Utkin VV; Poleshchuk AK; Zankisova IG; Mkrtchian SV; Krylova NP Probl Tuberk; 1971; 49(7):27-32. PubMed ID: 5004349 [No Abstract] [Full Text] [Related]
35. [Comparative data from an experimental-clinical study of new antituberculosis drugs]. Utkin VV Antibiotiki; 1972 Sep; 17(9):851-6. PubMed ID: 4631726 [No Abstract] [Full Text] [Related]
36. Rifampicin in the retreatment and original treatment of advanced pulmonary tuberculosis. Gyselen A Bull Int Union Tuberc; 1970 Jun; 43():60-3. PubMed ID: 4987555 [No Abstract] [Full Text] [Related]
37. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257 [TBL] [Abstract][Full Text] [Related]
38. [Dynamics of rifampicin and ethambutol resistance of strains of Koch bacilli isolated from patients with pulmonary tuberculosis 1973-1981]. Ionescu C; Timoşca S; Petreanu V; Petreanu C; Georgescu M; Martinescu T Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1982; 31(4):315-20. PubMed ID: 6304845 [No Abstract] [Full Text] [Related]
39. [Funtional status of the liver in patients with pulmonary tuberculosis treated with ethambutol and rifampicin]. Priss IS G Ital Chemioter; 1972; 19(2):29-31. PubMed ID: 4666008 [No Abstract] [Full Text] [Related]
40. Drug-resistant pulmonary tuberculosis treated with ethambutol, a rifamycin and a riminophenazine (B663). Donaldson R; Wallace A Br J Dis Chest; 1970 Jul; 64(3):161-3. PubMed ID: 4990938 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]